MedTrace Logo

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

NCT00373711 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-06-21

No results posted yet for this study

Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Conditions

Interventions

DRUG

Iodine-124

2 mCi, oral

DRUG

Iodine-123

2 mCi, oral

DRUG

F-18 FDG

10-15 mCi, iv

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru · Stanford University

  • Iain Ross McDougall · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373711 on ClinicalTrials.gov